PALI earnings date and last-quarter result: next report 2026-08-10, last quarter miss, P/E -1.79. Updated 2026-07-23.
Palisade Bio (PALI) Research Hub
Palisade Bio (PALI) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.23 USD (-7.52%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.79, market cap 0.34B. This hub links to the full technical, earnings and options research available for PALI.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.23 USD (-7.52%) |
| 52-week range | 1.21 USD – 2.29 USD |
| Trend regime | Range |
| 14-day RSI | 35.1 (Bearish) |
| Trailing P/E | -1.79 |
| Market cap | 0.34B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for PALI
Covered Call on PALI: how it works, illustrative setup around the real 1.23 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PALI: how it works, illustrative setup around the real 1.23 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PALI: how it works, illustrative setup around the real 1.23 USD price, max profit/loss, breakeven and when to use it. Educational.
PALI technical analysis: range, last 1.23 USD, RSI 35.1, 52w range 1.21 USD–2.29 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is PALI in?
Palisade Bio (PALI) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is PALI in an uptrend or downtrend?
As of 2026-10-26, PALI is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PALI's trailing P/E ratio?
PALI's trailing P/E is -1.79, with a market cap of 0.34B. See the earnings research page for full valuation detail.
When does PALI next report earnings?
PALI is next scheduled to report earnings on 2026-08-10.